Sanofi (SNY)
$57.73
Sanofi SA is a French multinational pharmaceutical company that focuses on the research, development, and distribution of healthcare products and services.
Performance
- $57.59$58.67$57.73
0.24%
Downside
Day's Volatility :1.84%
Upside
1.6%
- $42.63$58.97$57.73
26.16%
Downside
52 Weeks Volatility :27.71%
Upside
2.1%
Returns
| Period | Sanofi | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 17.86% | 5.1% | 0.0% |
6 Months | 20.12% | 4.9% | 0.0% |
1 Year | 8.86% | 16.6% | 0.0% |
3 Years | 11.97% | 13.2% | -22.3% |
Highlights
Market Capitalization | 145.6B |
Book Value | $58.1 |
Dividend Share | 3.76 |
Dividend Yield | 3.53% |
Earnings Per Share (EPS) | 1.86 |
PE Ratio | 31.04 |
PEG Ratio | 0.85 |
Wall Street Target Price | 59.89 |
Profit Margin | 8.95% |
Operating Margin TTM | 14.31% |
Return On Assets TTM | 4.16% |
Return On Equity TTM | 5.82% |
Revenue TTM | 47.1B |
Revenue Per Share TTM | 18.81 |
Quarterly Revenue Growth YOY | 7.5% |
Gross Profit TTM | 31.7B |
EBITDA | 11.8B |
Diluted Eps TTM | 1.86 |
Quarterly Earnings Growth YOY | -0.23 |
EPS Estimate Current Year | 4.27 |
EPS Estimate Next Year | 4.95 |
EPS Estimate Current Quarter | 0.86 |
EPS Estimate Next Quarter | 1.5 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 3.74%
Technicals Summary
Sell
Neutral
Buy
Sanofi is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Sanofi | 11.45% | 20.12% | 8.86% | 11.97% | 31.83% |
 Eli Lilly And Company | 16.91% | 15.71% | 57.48% | 254.28% | 712.74% |
 Johnson & Johnson | 3.45% | 3.47% | 2.72% | -4.61% | 29.48% |
 Merck & Co. Inc. | 4.76% | -4.96% | 9.17% | 55.09% | 41.18% |
 Abbvie Inc | 3.14% | 7.11% | 29.88% | 77.38% | 189.96% |
 Amgen Inc. | 2.58% | 17.48% | 26.01% | 44.83% | 58.43% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Sanofi | 31.04 | 31.04 | 0.85 | 4.27 | 0.06 | 0.04 | 0.04 | 58.1 |
Eli Lilly And Company | 112.41 | 112.41 | 0.86 | 16.41 | 0.59 | 0.14 | 0.01 | 15.06 |
Johnson & Johnson | 24.87 | 24.87 | 0.97 | 10.03 | 0.22 | 0.08 | 0.03 | 29.72 |
Merck & Co. Inc. | 21.82 | 21.82 | 0.08 | 8.06 | 0.33 | 0.11 | 0.03 | 17.19 |
Abbvie Inc | 64.47 | 64.47 | 0.47 | 10.88 | 0.54 | 0.08 | 0.03 | 3.84 |
Amgen Inc. | 55.27 | 55.27 | 2.23 | 19.49 | 0.49 | 0.04 | 0.03 | 11.03 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Sanofi | Buy | $145.6B | 31.83% | 31.04 | 8.95% |
Eli Lilly And Company | Buy | $821.9B | 712.74% | 112.41 | 18.86% |
Johnson & Johnson | Buy | $397.2B | 29.48% | 24.87 | 43.91% |
Merck & Co. Inc. | Buy | $300.6B | 41.18% | 21.82 | 21.99% |
Abbvie Inc | Buy | $341.6B | 189.96% | 64.47 | 9.71% |
Amgen Inc. | Buy | $174.3B | 58.43% | 55.27 | 10.12% |
Insights on Sanofi
Increasing Revenue
Revenue is up for the last 2 quarters, 11.11B → 21.20B (in $), with an average increase of 47.6% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, 1.13B → 2.24B (in $), with an average increase of 49.6% per quarter
Vs LLY
In the last 1 year, Eli Lilly And Company has given 57.5% return, outperforming this stock by 48.6%
Vs LLY
In the last 3 years, Eli Lilly And Company has given 254.3% return, outperforming this stock by 242.3%
Institutional Holdings
Dodge & Cox
3.08%FMR Inc
0.61%Fisher Asset Management, LLC
0.54%Boston Partners Global Investors, Inc
0.52%Bank of America Corp
0.44%BlackRock Inc
0.40%
Corporate Announcements
Sanofi Dividends September,2024
In the quarter ending September,2024. Sanofi has declared dividend of $2.04
Read More
Company Information
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. Originally, the corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo
Organization | Sanofi |
Employees | 86088 |
CEO | Mr. Paul Hudson |
Industry | Health Technology |
